This is an early operational milestone with no efficacy data — the stock may see a modest short-term pop on the news, but the real catalyst will be safety/efficacy readouts from the AUD cohort. Monitor for next data release from the trial.
Price Chart
Executive Summary
Clearmind Medicine announced enrollment of the first two patients with Alcohol Use Disorder in its Phase 1/2 CMND-100 clinical trial at Hadassah Medical Center. This is an early-stage operational milestone for a micro-cap biotech with no revenue, moving from healthy volunteers to the target patient population. The filing contains no financial data, efficacy results, or guidance — it is a routine clinical update for a pre-commercial company.
Key Facts
- First two AUD patients enrolled in CMND-100 trial at Hadassah Medical Center, Jerusalem
- First administration of CMND-100 to patients with Alcohol Use Disorder
- Trial designed to evaluate safety, tolerability, PK, and preliminary efficacy
- Company has evaluated CMND-100 at multiple doses in healthy participants previously
- CMND-100 is a proprietary non-hallucinogenic psychedelic-derived neuroplastogen candidate
- Company has 19 patent families including 32 granted patents
- Market cap approximately $1M
Financial Impact
No financial figures reported; pre-revenue clinical-stage company
Risk Factors
- Clinical trial failure risk — no efficacy data yet for CMND-100 in AUD patients
- Extreme micro-cap volatility — $1M market cap with history of large daily swings
- Dilution risk from multiple outstanding F-3 shelf registrations
- No revenue or near-term commercialization path
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-099433 |
| Document: ea030539001ex99-1.htm | 0001213900-26-099433 |
| Document: 0001213900-26-099433-index-headers.html | 0001213900-26-099433 |
| Document: 0001213900-26-099433-index.html | 0001213900-26-099433 |
| Document: 0001213900-26-099433.txt | 0001213900-26-099433 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $6.07 (+2.53%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $6.07 (−6.62%) |
Oct 16, 2026 11d ago | 6-K | $6.00 | awaiting T+60 | — | $6.07 (−1.17%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $6.07 (−2.57%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.07 (−8.03%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $6.07 (−8.03%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.07 (+614.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.07 (+614.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.07 (−11.57%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.07 (+543.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers